ZA200900553B - Rnai-Mediated inhibition of gremlin for treatment of IOP-related conditions - Google Patents

Rnai-Mediated inhibition of gremlin for treatment of IOP-related conditions

Info

Publication number
ZA200900553B
ZA200900553B ZA200900553A ZA200900553A ZA200900553B ZA 200900553 B ZA200900553 B ZA 200900553B ZA 200900553 A ZA200900553 A ZA 200900553A ZA 200900553 A ZA200900553 A ZA 200900553A ZA 200900553 B ZA200900553 B ZA 200900553B
Authority
ZA
South Africa
Prior art keywords
gremlin
iop
rnai
treatment
related conditions
Prior art date
Application number
ZA200900553A
Other languages
English (en)
Inventor
Jon E Chatterton
Abbot F Clark
Original Assignee
Alcon Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Res Ltd filed Critical Alcon Res Ltd
Publication of ZA200900553B publication Critical patent/ZA200900553B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA200900553A 2006-08-24 2007-08-24 Rnai-Mediated inhibition of gremlin for treatment of IOP-related conditions ZA200900553B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US83982606P 2006-08-24 2006-08-24

Publications (1)

Publication Number Publication Date
ZA200900553B true ZA200900553B (en) 2010-04-28

Family

ID=39032079

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200900553A ZA200900553B (en) 2006-08-24 2007-08-24 Rnai-Mediated inhibition of gremlin for treatment of IOP-related conditions

Country Status (11)

Country Link
US (3) US20080051361A1 (enExample)
EP (1) EP2059597A2 (enExample)
JP (1) JP2010501188A (enExample)
KR (1) KR20090042297A (enExample)
CN (2) CN101517081A (enExample)
AU (1) AU2007286545A1 (enExample)
BR (1) BRPI0715821A2 (enExample)
CA (1) CA2659464A1 (enExample)
MX (1) MX2009001896A (enExample)
WO (1) WO2008024983A2 (enExample)
ZA (1) ZA200900553B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006006948A2 (en) * 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
GB0708662D0 (en) * 2007-05-04 2007-06-13 Galapagos Nv shRNA sequences
AU2008308784B2 (en) * 2007-10-01 2013-07-18 Arrowhead Research Corporation Self complementary AAV-mediated delivery of interfering RNA molecules to treat or prevent ocular disorders
BRPI0802525A2 (pt) 2008-07-11 2010-03-09 Kiyoshi Hashiba endoscópio cirúrgico
WO2010090762A1 (en) 2009-02-04 2010-08-12 Rxi Pharmaceuticals Corporation Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
WO2011072091A1 (en) * 2009-12-09 2011-06-16 Quark Pharmaceuticals, Inc. Methods and compositions for treating diseases, disorders or injury of the cns
US9095504B2 (en) 2010-03-24 2015-08-04 Rxi Pharmaceuticals Corporation RNA interference in ocular indications
PL2796150T3 (pl) 2011-12-15 2021-08-30 Bioneer Corporation Nowe koniugaty oligonukleotydowe i ich zastosowanie
KR101722948B1 (ko) 2012-01-05 2017-04-04 (주)바이오니아 리간드가 결합된 이중나선 올리고 ｒｎａ 구조체 및 그 제조방법
RU2577227C1 (ru) 2012-01-05 2016-03-10 Байонир Корпорейшн Высокоэффективная двухспиральная олиго-рнк конструкция типа наночастицы и способ ее изготовления
JP5906327B2 (ja) 2012-01-18 2016-04-20 バイオニア コーポレーションＢｉｏｎｅｅｒ Ｃｏｒｐｏｒａｔｉｏｎ 磁性ナノ粒子−ＳＡＭｉＲＮＡ複合体およびその製造方法
WO2013137686A1 (ko) * 2012-03-15 2013-09-19 서울대학교 산학협력단 그렘린-1에 대한 항체
GB201215857D0 (en) * 2012-09-05 2012-10-24 Sylentis Sau siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
AU2012389270B2 (en) * 2012-09-05 2018-11-08 Sylentis S.A.U. siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
CA2917299C (en) 2013-07-05 2020-07-21 Bioneer Corporation Improved nanoparticle type oligonucleotide structure having high efficiency and method for preparing same
WO2015132303A1 (en) 2014-03-04 2015-09-11 Sylentis Sau Sirnas and their use in methods and compositions for the treatment and/or prevention of eye conditions
CA2947270A1 (en) 2014-04-28 2015-11-05 Rxi Pharmaceuticals Corporation Methods for treating cancer using nucleic acids targeting mdm2 or mycn
JP2017200928A (ja) * 2017-05-31 2017-11-09 シレンティス・エセ・ア・ウ ｓｉＲＮＡならびに眼の状態の処置および／または予防のための方法および組成物におけるその使用
CN106978509B (zh) * 2017-06-07 2018-10-26 中南大学湘雅二医院 青光眼诊断分子标记物lncRNAs ENST00000607393、试剂盒及应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1966725A (zh) * 2001-10-31 2007-05-23 爱尔康公司 骨形态生发蛋白(bmp)、bmp受体和bmp结合蛋白及它们在诊断和治疗青光眼中的用途
US20040138163A1 (en) * 2002-05-29 2004-07-15 Mcswiggen James RNA interference mediated inhibition of vascular edothelial growth factor and vascular edothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
WO2006006948A2 (en) * 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
US20060141049A1 (en) * 2003-11-12 2006-06-29 Allergan, Inc. Triamcinolone compositions for intravitreal administration to treat ocular conditions
TW200639253A (en) * 2005-02-01 2006-11-16 Alcon Inc RNAi-mediated inhibition of ocular targets

Also Published As

Publication number Publication date
US20120077864A1 (en) 2012-03-29
CN102743767A (zh) 2012-10-24
US20080051361A1 (en) 2008-02-28
BRPI0715821A2 (pt) 2013-07-23
MX2009001896A (es) 2009-04-17
AU2007286545A1 (en) 2008-02-28
JP2010501188A (ja) 2010-01-21
KR20090042297A (ko) 2009-04-29
WO2008024983A3 (en) 2008-10-09
CA2659464A1 (en) 2008-02-28
US20100305193A1 (en) 2010-12-02
WO2008024983A2 (en) 2008-02-28
CN101517081A (zh) 2009-08-26
EP2059597A2 (en) 2009-05-20

Similar Documents

Publication Publication Date Title
IL194114A0 (en) Treatment of cns conditions
GB2454797B (en) Treatment of wastewater
EP2032131A4 (en) Methods of Treatment
ZA200900884B (en) Method of scale inhibition
SG10201404955RA (en) Rnai inhibition of alpha-enac expression
PL2029155T3 (pl) Ulepszony sposób leczenia szpiczaka mnogiego
IL195803A0 (en) Compositions and methods for sirna inhibition of angiogenesis
EP2066589A4 (en) WATER TREATMENT SYSTEM
ZA200809203B (en) Rnai-mediated inhibition of tumor necrosis factor alpha-related conditions
ZA200901364B (en) Method of treatment of photodermatoses
ZA201008192B (en) A phytosystem for treatment of sewage
EP2013404A4 (en) OPERATING PROCESS FOR DRYERS
EP2072470A4 (en) PROCESS FOR RECYCLING WASTEWATER
GB0610746D0 (en) Method of treatment
GB0608190D0 (en) Method of purification
GB0701722D0 (en) Inhibition of gene expression
EP2164494A4 (en) Methods of Treatment
GB0605685D0 (en) Inhibition of tumour growth
EP2188219A4 (en) METHOD FOR WATER TREATMENT COMPRISING NON-POLAR COMPOUNDS
ZA200805601B (en) RNAI-mediated inhibition of IGF1R for treatment of ocular angiogenesis
GB0723100D0 (en) Treatment of HFnEF
EP2344424A4 (en) ELIMINATION OF ARSENIC FROM WATER
EP2094385A4 (en) METHOD OF WASTE WATER TREATMENT
ZA200903242B (en) Treatment for multiple myeloma
EP2203432A4 (en) PROCESSING METHOD